Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    -0.50 (-0.75%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.24m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

PCA Dealing

12 Feb 2026 17:40

RNS Number : 8457S
Venture Life Group PLC
12 February 2026
 

12 February 2026

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

PCA Dealing

 

Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that it was notified on 11 February 2026 that Lewis Arthur, a PCA of Sarah Arthur, Interim Commercial Director of the Company, purchased 2,959 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a price of 67.38p per Ordinary Share on 29 January 2026 (the "Purchase").

Following the Purchase, Sarah Arthur's beneficial interest in the Company, including those held by her PCA, is 2,959 Ordinary Shares, representing 0.002 per cent. of the issued share capital of the Company.

 

For further information, please contact:

Venture Life Group PLC +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 The notification below, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail on the share dealings.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Lewis Arthur

2

 

Reason for the notification

 

a)

 

Position/status

 

PCA of Sarah Arthur, Interim Commercial Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

67.38 pence

2,959

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - Single transaction

 

 

 

 

 

 

e)

 

Date of the transaction

 

29 January 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXAAFDPKEFA
Date   Source Headline
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.